
CLAIMS

What is claimed is:


1. Use of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anemia associated with or secondary to chronic kidney disease, in a subject in need thereof, wherein the medicament is to be orally administered for at least about 24, 28, 32, 36, 40, 44, 48, or 52 weeks.


2. Use of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anemia associated with or secondary to chronic kidney disease, in a subject in need thereof, wherein hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the subject.


3. Use of of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anemia associated with or secondary to chronic kidney disease, in a subject in need thereof, wherein hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.

4. Use of a compound that is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure of Compound **1**,



(Compound **1**),

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of anemia associated with or secondary to chronic kidney disease, in a subject in need thereof, wherein the medicament is to be orally administered for at least about 53-260 weeks.

5. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 4, wherein hemoglobin levels are increased to about 10.0 – 13.0 g/dL from a baseline hemoglobin level in the subject.

6. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 4, wherein hemoglobin levels are maintained or controlled at about 10.0 – 13.0 g/dL.

7. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 24 weeks.

8. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 28 weeks.

9. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 32 weeks.

10. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 36 weeks.

11. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 40 weeks.

12. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 44 weeks.

13. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 48 weeks.

14. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-3, wherein the medicament is to be administered to the subject for at least about 52 weeks.

15. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicament is to be administered to the subject for at least about 53 weeks.

16. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicament is to be administered to the subject for at least about 64 weeks.

17. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 76 weeks.

18. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 88 weeks.

19. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 104 weeks.

20. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 116 weeks.

21. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 128 weeks.

22. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 140 weeks.

23. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 156 weeks.

24. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 168 weeks.

25. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subjectfor at least about 180 weeks.

26. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 192 weeks.

27. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 208 weeks.

28. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 4-6, wherein the medicamentis to be administered to the subject for at least about 260 weeks.

29. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-28, wherein the subject has non-dialysis dependent chronic kidney disease (NDD-CKD).

30. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-28, wherein the subject has dialysis-dependent chronic kidney disease (DD-CKD).

31. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-30, wherein the subject has been previously treated with an erythropoiesis stimulating agent (ESA).

32. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 31, wherein the subject has been previously treated with an erythropoiesis stimulating agent (ESA) within about eight weeks prior to or during a screening period before administering the medicament.

33. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 31, wherein the subject has been previously treated with an erythropoiesis stimulating agent (ESA) within about six weeks prior to or during a screening period before administering the medicament.

34. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 32 or 33, wherein the screening period is up to about eight weeks.

35. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 32 or 33, wherein the screening period is up to about 6 weeks.

36. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 32 or 33, wherein the screening period is up to about 4 weeks.

37. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 31-36, wherein the erythropoiesis stimulating agent is epoetin, darbepoetin alfa (DA), or methoxy polyethylene glycol-epoetin beta (epoetin beta pegol).

38. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the epoetin is epoetin alfa, epoetin beta, epoetin gamma, epoetin kappa, or a combination thereof.

39. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 38, wherein the subject has been previously treated with epoetin alfa in an amount of about 10 U/kg to about 500 U/kg 3 times weekly.

40. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the subject has been previously treated with epoetin beta pegol in a dosage amount of about 0.6 mcg/kg to about 1.20 mcg/kg once every two weeks.

41. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the subject has been previously treated with epoetin beta pegol in a dosage amount of about 0.6 mcg/kg to about 1.20 mcg/kg once monthly.

42. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the subject has been previously treated with epoetin at a dose of about ≥ 4500 IU weekly.

43. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the subject has been previously treated with epoetin at a dose of about <4500 IU.

44. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the subject has been previously treated with darbepoetin alfa (DA) in a dosage amount of about 0.45 mcg/kg to about 0.75 mcg/kg once every four weeks.

45. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the subject has been previously treated with darbepoetin alfa (DA) in a dosage amount of about 0.45 mcg/kg to about 0.75 mcg/kg once every two weeks.

46. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the subject has been previously treated with darbepoetin alfa (DA) in a dosage amount of about 0.45 mcg/kg to about 0.75 mcg/kg once a week.

47. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the subject has been previously treated with darbepoetin alfa in a dosage amount of about ≥ 15 μg weekly.

48. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 37, wherein the subject has been previously treated with darbepoetin alfa in a dosage amount of about < 15 μg weekly.

49. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-30, wherein the subject has not been previously treated with an erythropoiesis stimulating agent (ESA).

50. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-49, wherein the medicament is to be administered at a dosage comprising about 150-600 mg**.**

51. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-50, wherein the medicament is to be administered at a dosage comprising about 150 mg**.**

52. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-50, wherein the medicament is to be administered at a dosage comprising about 300 mg**.**

53. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-50, wherein the medicament is to be administered at a dosage comprising about 450 mg**.**

54. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-50, wherein the medicament is to be administered at a dosage comprising about 600 mg.

55. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-54, wherein the medicament is to be administered once daily.

56. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-54, wherein the medicament is to be administered once a week.

57. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-54, wherein the medicament is to be administered three times a week.

58. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-50, wherein the medicament is to be administered once daily.

59. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-58, wherein the medicament is to be administered three times a week.

60. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1, 4 and 7-59, wherein the subject has a hemoglobin level of about 8.0 g/dL to about 13.0 g/dL.

61. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 7-59, wherein the subject has a hemoglobin level of about ≥13.0 g/dL.

62. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-61, wherein the subject has a baseline hemoglobin level of about <10 g/dL.

63. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 2, 5, 7-59 and 62, wherein the hemoglobin levels are increased to about 10.0-11.0 g/dL.

64. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 2, 5, 7-59 and 62, wherein the hemoglobin levels are increased to about 11.0-13.0 g/dL.

65. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 7-59 and 62, wherein the medicament is to be administered comprisingadjusting the dosage by about 150 mg if the subject's hemoglobin (Hb) level is < 10.0 g/dL or > 11.5 g/dL.

66. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 65, wherein the medicament is to be administered further comprising increasing the dosage, and the subject's hemoglobin (Hb) level is < 10.0 g/dL.

67. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to claim 65, wherein the medicament is to be administered further decreasing the dosage.

68. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 7-59, 62, and 65-67, wherein the medicament is to be administered further comprising adjusting the dosage no more than once in at least every 2 weeks.

69. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 7-59, 62, and 65-67, wherein the medicament is to be administered further comprising adjusting the dosage no more than once in at least every 4 weeks.

70. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 7-59, 62, and 65-67, wherein the medicament is to be administered further comprising adjusting the dosage no more than once in at least every 6 weeks.

71. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 7-59and 62, wherein the medicament is to be administered further comprising decreasing the dose no more than once in at least every 2 weeks.

72. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 3, 6, 7-59 and 62, wherein the hemoglobin levels are maintained or controlled at about 10.0 – 12.0 g/dL.

73. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 3, 6, 7-59 and 62, wherein the hemoglobin levels are maintained or controlled at about 11.0 – 13.0 g/dL.

74. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-73, wherein the patient has a serum ferritin level of about ≥ 100 ng/mL and/or a transferrin saturation (TSAT) of ≥ 20%.

75. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-74, wherein the patient has a decrease in serum ferritin level relative to a baseline level.

76. The use of Compound 1, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-75, wherein the patient is ≥ 18 years old.